Menu

Press Releases

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

, ,

Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent Amgen to Webcast Investor Call at AHA Scientific Sessions 2014 THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational […]

European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

, , ,

Once-Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 18, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first […]

Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today

, , ,

Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J., November 17, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data […]

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

, , ,

CHICAGO, November 17, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN® (ezetimibe/simvastatin) – which combines simvastatin with the non-statin ZETIA® (ezetimibe) — experienced significantly fewer major […]

Sequenta Enters Agreement with Illumina on In Vitro Diagnostic (IVD) Kit for Sequencing-Based Minimal Residual Disease Testing

,

SOUTH SAN FRANCISCO, Calif. NOVEMBER 17, 2014 – Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical […]

Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

, , , ,

KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH, November 16, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 […]

Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment

,

– Multiple Clinical Presentations at Kidney Week 2014 – – Studies Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults Regardless of Dialysis or Transplant History – – New aHUS Registry Data Enhance the Understanding of aHUS – CHESHIRE, Conn. November 15, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data […]

BridgeSpan Health Offers Oregon Residents Guidance and Innovative Health Insurance Options on the Public Exchange

,

Northwest Insurer Focuses on Affordable, Consumer-Friendly Plans PORTLAND, Ore. — November 14, 2014 – Individuals and families in Oregon looking for health care coverage as part of the Affordable Care Act, will have more choices on November 15 when open enrollment begins on the Health Insurance Exchange. BridgeSpan Health will offer several new, comprehensive plans […]

BridgeSpan Health Offers Utah Residents Guidance and Innovative Health Insurance Options on the Public Exchange

,

Northwest Insurer Focuses on Affordable, Consumer-Friendly Plans SALT LAKE CITY — November 14, 2014 – Individuals and families in Utah looking for health care coverage as part of the Affordable Care Act, will have more choices on November 15 when open enrollment begins on the Health Insurance Exchange. BridgeSpan Health will offer several new, comprehensive […]

GE Healthcare Life Sciences to open biopharmaceutical Technology and Training Laboratory in Turkey

, ,

Supports Turkey’s ambitions to expand domestic biopharmaceutical industry Laboratory to be a key component of GE’s new Innovation Center in Istanbul Chalfont St. Giles, UK and Istanbul, Turkey – 14 November 2014 — GE Healthcare Life Sciences, a global tools, technologies and services provider in life science research and biopharmaceutical manufacturing, will open a Technology and […]

«‹ 80 81 82 83›»